Bristol Myers Squibb Data at ASH 2025 Showcase Potential of Hematology Pipeline and Build Momentum for Next Generation ...
Iberdomide shows deep and sustained responses in newly diagnosed multiple myeloma First-in-class lymphoma CELMoD™ agent, golcadomide, delivers durable responses in combinations across aggressive and indolent lymphomas First-in-class BCL6 ligand-directed …